For the second year in a row, and for only the second time since 2014, R&D productivity for pharma’s top 30 companies is down. What is driving this decrease, and what does it mean for the future? Using Catenion’s annual review as a basis, In Vivo takes a look at growth rankings across the pharma industry, examining the trends among midsize pharma companies (many of whom being targeted by AstraZeneca’s R&D strategy), R&D productivity among other names in Big Pharma, and more, and tackles the question of what the future may bring.